143 related articles for article (PubMed ID: 9025779)
1. Complementation of temperature-sensitive topoisomerase II mutations in Saccharomyces cerevisiae by a human TOP2 beta construct allows the study of topoisomerase II beta inhibitors in yeast.
Meczes EL; Marsh KL; Fisher LM; Rogers MP; Austin CA
Cancer Chemother Pharmacol; 1997; 39(4):367-75. PubMed ID: 9025779
[TBL] [Abstract][Full Text] [Related]
2. Carbamate analogues of amsacrine active against non-cycling cells: relative activity against topoisomerases IIalpha and beta.
Turnbull RM; Meczes EL; Perenna Rogers M; Lock RB; Sullivan DM; Finlay GJ; Baguley BC; Austin CA
Cancer Chemother Pharmacol; 1999; 44(4):275-82. PubMed ID: 10447574
[TBL] [Abstract][Full Text] [Related]
3. Molecular cloning and expression of the Candida albicans TOP2 gene allows study of fungal DNA topoisomerase II inhibitors in yeast.
Keller BA; Patel S; Fisher LM
Biochem J; 1997 May; 324 ( Pt 1)(Pt 1):329-39. PubMed ID: 9164874
[TBL] [Abstract][Full Text] [Related]
4. Analysis of yeast DNA topoisomerase II mutants resistant to the antitumor drug amsacrine.
Wasserman RA; Wang JC
Cancer Res; 1994 Apr; 54(7):1795-800. PubMed ID: 8137294
[TBL] [Abstract][Full Text] [Related]
5. The top2-5 mutant of yeast topoisomerase II encodes an enzyme resistant to etoposide and amsacrine.
Jannatipour M; Liu YX; Nitiss JL
J Biol Chem; 1993 Sep; 268(25):18586-92. PubMed ID: 8395511
[TBL] [Abstract][Full Text] [Related]
6. A temperature sensitive topoisomerase II allele confers temperature dependent drug resistance on amsacrine and etoposide: a genetic system for determining the targets of topoisomerase II inhibitors.
Nitiss JL; Liu YX; Hsiung Y
Cancer Res; 1993 Jan; 53(1):89-93. PubMed ID: 8380128
[TBL] [Abstract][Full Text] [Related]
7. Functional expression of human topoisomerase II alpha in yeast: mutations at amino acids 450 or 803 of topoisomerase II alpha result in enzymes that can confer resistance to anti-topoisomerase II agents.
Hsiung Y; Jannatipour M; Rose A; McMahon J; Duncan D; Nitiss JL
Cancer Res; 1996 Jan; 56(1):91-9. PubMed ID: 8548781
[TBL] [Abstract][Full Text] [Related]
8. Mutations at arg486 and glu571 in human topoisomerase IIalpha confer resistance to amsacrine: relevance for antitumor drug resistance in human cells.
Patel S; Keller BA; Fisher LM
Mol Pharmacol; 2000 Apr; 57(4):784-91. PubMed ID: 10727526
[TBL] [Abstract][Full Text] [Related]
9. Human DNA topoisomerases II alpha and II beta can functionally substitute for yeast TOP2 in chromosome segregation and recombination.
Jensen S; Redwood CS; Jenkins JR; Andersen AH; Hickson ID
Mol Gen Genet; 1996 Aug; 252(1-2):79-86. PubMed ID: 8804406
[TBL] [Abstract][Full Text] [Related]
10. DNA topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in Saccharomyces cerevisiae.
Ishida R; Hamatake M; Wasserman RA; Nitiss JL; Wang JC; Andoh T
Cancer Res; 1995 Jun; 55(11):2299-303. PubMed ID: 7757979
[TBL] [Abstract][Full Text] [Related]
11. Yeast topoisomerase II mutants resistant to anti-topoisomerase agents: identification and characterization of new yeast topoisomerase II mutants selected for resistance to etoposide.
Liu YX; Hsiung Y; Jannatipour M; Yeh Y; Nitiss JL
Cancer Res; 1994 Jun; 54(11):2943-51. PubMed ID: 8187080
[TBL] [Abstract][Full Text] [Related]
12. Complementation of a yeast top2ts mutation by a cDNA encoding rat DNA topoisomerase II alpha.
Yoon JH; Park SH; Cho HA; Seong RH; Hong SH; Park SD
Mol Gen Genet; 1996 Nov; 253(1-2):81-8. PubMed ID: 9003290
[TBL] [Abstract][Full Text] [Related]
13. Mutations in the gyrB domain of eukaryotic topoisomerase II can lead to partially dominant resistance to etoposide and amsacrine.
Nitiss JL; Vilalta PM; Wu H; McMahon J
Mol Pharmacol; 1994 Oct; 46(4):773-7. PubMed ID: 7969059
[TBL] [Abstract][Full Text] [Related]
14. Ectopic expression of inactive forms of yeast DNA topoisomerase II confers resistance to the anti-tumour drug, etoposide.
Vassetzky YS; Alghisi GC; Roberts E; Gasser SM
Br J Cancer; 1996 May; 73(10):1201-9. PubMed ID: 8630279
[TBL] [Abstract][Full Text] [Related]
15. Identification of yeast DNA topoisomerase II mutants resistant to the antitumor drug doxorubicin: implications for the mechanisms of doxorubicin action and cytotoxicity.
Patel S; Sprung AU; Keller BA; Heaton VJ; Fisher LM
Mol Pharmacol; 1997 Oct; 52(4):658-66. PubMed ID: 9380029
[TBL] [Abstract][Full Text] [Related]
16. Using yeast to study resistance to topoisomerase II-targeting drugs.
Nitiss JL
Cancer Chemother Pharmacol; 1994; 34 Suppl():S6-13. PubMed ID: 8070029
[TBL] [Abstract][Full Text] [Related]
17. Functional expression of a Drosophila gene in yeast: genetic complementation of DNA topoisomerase II.
Wyckoff E; Hsieh TS
Proc Natl Acad Sci U S A; 1988 Sep; 85(17):6272-6. PubMed ID: 2842762
[TBL] [Abstract][Full Text] [Related]
18. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
19. Atypical multidrug resistance may be associated with catalytically active mutants of human DNA topoisomerase II alpha.
Okada Y; Tosaka A; Nimura Y; Kikuchi A; Yoshida S; Suzuki M
Gene; 2001 Jul; 272(1-2):141-8. PubMed ID: 11470519
[TBL] [Abstract][Full Text] [Related]
20. Yeast cells expressing differential levels of human or yeast DNA topoisomerase II: a potent tool for identification and characterization of topoisomerase II-targeting antitumour agents.
van Hille B; Hill BT
Cancer Chemother Pharmacol; 1998; 42(5):345-56. PubMed ID: 9771947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
